Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Janux Therapeutics (JANX) Equity Average (2021 - 2025)

Historic Equity Average for Janux Therapeutics (JANX) over the last 5 years, with Q3 2025 value amounting to $983.5 million.

  • Janux Therapeutics' Equity Average rose 4972.59% to $983.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $983.5 million, marking a year-over-year increase of 4972.59%. This contributed to the annual value of $683.6 million for FY2024, which is 10555.59% up from last year.
  • Latest data reveals that Janux Therapeutics reported Equity Average of $983.5 million as of Q3 2025, which was up 4972.59% from $1.0 billion recorded in Q2 2025.
  • Janux Therapeutics' 5-year Equity Average high stood at $1.0 billion for Q1 2025, and its period low was $305.4 million during Q2 2023.
  • Its 5-year average for Equity Average is $533.8 million, with a median of $371.5 million in 2021.
  • In the last 5 years, Janux Therapeutics' Equity Average tumbled by 1273.95% in 2023 and then skyrocketed by 14215.96% in 2024.
  • Janux Therapeutics' Equity Average (Quarter) stood at $371.5 million in 2021, then decreased by 12.22% to $326.1 million in 2022, then increased by 6.29% to $346.6 million in 2023, then soared by 142.16% to $839.4 million in 2024, then grew by 17.17% to $983.5 million in 2025.
  • Its Equity Average stands at $983.5 million for Q3 2025, versus $1.0 billion for Q2 2025 and $1.0 billion for Q1 2025.